HC Wainwright Reiterates Buy Rating for MiNK Therapeutics (NASDAQ:INKT)

MiNK Therapeutics (NASDAQ:INKT)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $9.00 price target on the stock.

MiNK Therapeutics Trading Down 4.5 %

Shares of INKT stock opened at $0.68 on Wednesday. The company’s fifty day simple moving average is $0.79 and its 200-day simple moving average is $0.90. MiNK Therapeutics has a 52 week low of $0.57 and a 52 week high of $1.90. The company has a market cap of $23.55 million, a PE ratio of -1.13 and a beta of 0.06.

MiNK Therapeutics (NASDAQ:INKT) last issued its earnings results on Tuesday, August 13th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.03. Equities research analysts expect that MiNK Therapeutics will post -0.33 EPS for the current fiscal year.

Institutional Trading of MiNK Therapeutics

An institutional investor recently raised its position in MiNK Therapeutics stock. Renaissance Technologies LLC boosted its position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 21.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 127,841 shares of the company’s stock after purchasing an additional 22,613 shares during the period. Renaissance Technologies LLC owned approximately 0.37% of MiNK Therapeutics worth $121,000 at the end of the most recent reporting period. 2.87% of the stock is currently owned by institutional investors.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.